The company took advantage of a boom in its share price following a successful Phase IIb trial.
The Israeli company is seeking to raise $15 million to fund the trials.
Teva announced that it was discontinuing a trial of fremanezumab for chronic cluster headache.
The agreement could generate as much as $150 million in annual revenue for the Israeli company.
Facilities will also open in Petah Tikva and Haifa in a unique model that combines incubator, co-working space and access to hospital infrastructures.
Beyeonics Augmented/Virtual Reality vision capabilities replace surgical microscopes and allow real-time integration of an unlimited amount of data.
The company's share price has risen 118% since Kare Schultz became CEO in November, and 23.5% in the past month. What has changed?
Galmed can now begin a Phase III trial on the drug for the treatment of inflammation caused by fatty liver disease.
Amai Proteins designs sweet proteins that do not affect the sugar levels in the blood.
Cannabics seeks to match cannabis compounds to treatment of specific tumors.
The company's robot both guides medical devices to the right place and inserts them and moves them into and within the body.